Mito Biopharma has established expertise and know-how that guide the medicinal chemistry development for various indications. Mito Biopharma has signed an R&D collaboration with Rutgers University to implement a drug discovery program utilizing existing synthetic chemistry expertise. Moreover, Mito Biopharma has enhanced its discovery program with outside CRO expertise to allow rapid synergy to transition to lead compound characterization. The drug discovery team is closely working with the biology team as well as outside CROs to screen for leads with desired pharmacology profiles as well as desired PD, PK, and ADME properties. The company has established strong pipelines and intellectual property positions and continues to evolve new leads. Mito Biopharma anticipates the initiation of IND-enabling studies in 2021.